HYPO-RT-PC phase 3 trial

SEP 10, 2019

Congratulations to all the 12 Swedish and Danish centers that have contributed to the HYPO-RT-PC phase 3 trial!

As the first published randomised trial on ultra-hypofractionated radiotherapy for prostate cancer, Lancet 18 2019, this groundbreaking study with 1,200 patients will lead to an increased use of ultra-hypofractionation. Fiducial markers will thereby become even more important.

We are happy and thankful that all centers, except one, that participated in this trial currently use Gold Anchors for their prostate treatments! To find out why, see GoldAnchorMarker.com.

Johnny Mattebo

Vice President of Sales

Privacy Preference Center


    Cookies that are necessary for the site to function properly.

    gdpr, pll_language, lang,


    Cookies that are used to track advertisement performance

    lidc, bcookie, bscookie, UserMatchHistory, test_cookie, lissc


    These are used to track user interaction and detect potential problems. These help us improve our services by providing analytical data on how users use this site.

    _ga, _gat_, gid